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Abstract
Monoamine oxidase (MAO) exists as two isoenzymes and 
plays a central role in the metabolism of monoamine neu­
rotransmitters. In this study we compared the neurochemi­
cal phenotypes of previously described subjects with geneti­
cally determined selective lack of MAO-A or a lack of both 
MAO-A and MAO-B with those of two subjects with a pre­
viously described X chromosome microdeletion in whom we 
now demonstrate selective MAO-B deficiency. Mapping of 
the distal deletion breakpoint demonstrates its location in 
intron 5 of the MAO-B gene, with the deletion extending 
proximally into the Norrie disease gene. In contrast to the 
borderline mental retardation and abnormal behavioral 
phenotype in subjects with selective MAO-A deficiency and 
the severe mental retardation in patients with combined 
MAO-A/MAO-B deficiency and Norrie disease, the MAO- 
B-deficient subjects exhibit neither abnormal behavior nor 
mental retardation. Distinct neurochemical profiles charac­
terize the three groups of MAO-deficient patients. In MAO- 
A-deficient subjects, there is a marked decrease in deami- 
nated catecholamine metabolites and a concomitant marked 
elevation of O-methylated amine metabolites. These neuro­
chemical changes are only slightly exaggerated in patients 
with combined lack of MAO-A and MAO-B. In contrast, the 
only biochemical abnormalities detected in subjects with the 
MAO-B gene deletion are a complete absence of platelet 
MAO-B activity and an increased urinary excretion of phe- 
nylethylamine. The differences in neurochemical profiles 
indicate that, under normal conditions, MAO-A is consider­
ably more important than MAO-B in the metabolism of bio­
genic amines, a factor likely to contribute to the different 
clinical phenotypes. (J. Clin. Invest. 1996. 97:1010-1019.) 
Key words: catecholamines • Norrie disease • metabolism • 
metanephrines • dihydroxyphenylglycol
Address correspondence to Dr. Jacques W.M. Lenders, Department 
of Medicine, Division of General Internal Medicine, St. Radboud 
University Hospital, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, 
The Netherlands. Phone: 31-24-3614782; FAX: 31-24-3541734; E-mail: 
i n wg j  1 @ A ZN VX1. AZN.NL
Received for publication 28 July 1995 and accepted in revised form  
29 November 1995.
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/96/02/1010/10 $2.00
Volume 97» Number 4, February 1996,1010-1019
Introduction
Monoamine oxidase (MAO),1 an enzyme that plays a crucial 
role in the metabolic degradation of biogenic amines, exists in 
two functional forms: MAO-A and MAO-B (1-3). The two 
isoenzymes have different substrate and inhibitor specificities 
and are encoded by two genes on the short arm of the X chro­
mosome (4).
Combined loss of MAO-A and MAO-B activity (MAO- 
AB) has been described in some patients with an X chromo­
some deletion that includes not only the Norrie disease gene 
but also the MAO-A and MAO-B genes (5-9). In addition to 
the blindness, hearing loss, and variable mental retardation 
that characterize Norrie disease (10), patients with the addi­
tional deletion of both MAO genes show profound mental re­
tardation, autistic-like behavior, atonic seizures, altered pe­
ripheral autonomic function, and profound alterations in 
biogenic amine metabolism (5, 6, 8). More recently, selective 
loss of MAO-A activity due to a point mutation in exon 8 of 
the MAO-A gene was described in a Dutch kindred (11, 12). 
In this kindred, selective MAO-A deficiency was associated 
with a clinical phenotype characterized by borderline mental 
retardation and impaired impulse control, including a propen­
sity towards stress-induced aggression.
Understanding the consequences of genetic deficiencies of 
MAO isoenzymes requires an understanding of the role of 
these enzymes in the metabolism of biogenic amines. In addi­
tion to inactivating catecholamines and their O-methylated 
metabolites, MAO deaminates other biogenic amines includ­
ing 5-hydroxytryptamine (5-HT) and the trace amines phenyl- 
ethylamine, m-tyramine, and p-tyramine (13). The catechol­
amines and their deaminated metabolites are also subject 
to O-methylation by catechol-0-methyltransferase (COMT). 
MAO and COMT, in combination with alcohol dehydroge­
nase, are responsible for the production of a wide range of cat­
echolamine metabolites, which for the purpose of this study 
can be divided into two groups: deaminated metabolites and 
O-methylated amine metabolites (Fig. 1).
The redundant nature of catecholamine metabolism en­
ables one pathway to compensate for blockade of the other, so
1. Abbreviations used in this paper: COMT, catechoI-O-methyl trans­
ferase; DA, dopamine; DHPG, dihydroxyphenylglycol; DOPA, dihy- 
droxyphenylalanine; DOPAC, dihydroxyphenylacetic acid; EPI, epi­
nephrine; 5-HT, 5-hydroxytryptamine; HVA, homovanillic acid; 
MAO, monoamine oxidase; MHPG, methoxyhydroxyphenylglycol; 
VMA, vanillylmandelic acid.
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Figure 1. The metabolic pathways 
of degradation of NE, EPI, and 
DA. The deaminated metabolites 
are DHPG , D O PA C, dihydroxy- 
mandelic acid (D H M A), dihy- 
droxy-phenylethanol (D O PET ), 
methoxyhydroxyphenylethanol 
(MOPET), HVA, MHPG, and 
VMA. The O-methylated amine 
metabolites are normetanephrine 
(NMN), metanephrine (M N ), and 
3-MT. DBH, D A  3-hydroxylase; 
PNMT, phenylethanolamine-JV- 
methyltransferase; ADH, alcohol 
dehydrogenase.
that reduced or absent activity of MAO leads to a decrease in 
production of deaminated metabolites and an increase in that 
of O-methylated amine metabolites (14, 15). Thus, simulta­
neous measurements of these metabolites are useful for neuro­
chemical phenotyping of patients with disorders of catechol­
amine metabolism (16).
The relative roles of COMT and MAO in the metabolic 
degradation of catecholamines are well established; on the 
other hand, those of the isoenzymes of MAO are not clear but 
are important for understanding the basis of therapeutic inter­
ventions involving specific inhibition of one or the other of the 
two MAO isoenzymes. Additionally, establishing the relative 
roles of MAO-A and MAO-B may also provide insight into 
how neurochemical alterations associated with deficiencies of 
the two isoenzymes give rise to clinical syndromes.
In the present study, we report on two subjects with a hith­
erto undescribed selective deficiency of MAO-B due to a mi­
crodeletion of the X chromosome, extending from the Norrie 
disease gene to within the MAO-B gene (17). For comparison, 
the neurochemical characteristics of previously described pa­
tients with combined MAO-AB deficiency and selective 
MAO-A deficiency are reported in greater detail, including a 
comprehensive analysis of plasma catecholamine metabolites 
(Fig. 1). These comparisons enabled examination of the rela­
tive roles of MAO-A and MAO-B in the metabolic degrada­
tion of catecholamines and other biogenic amines, including 
5-HT and the trace amines.
Methods
Subjects. Two brothers (ages: 29 and 31 yr) with a complete selective 
loss of MAO-B activity due to a microdeletion of the Norrie disease 
and MAO-B genes participated in the study. Norrie disease, charac­
terized by blindness, was diagnosed at the ages of 5 and 18 mo. Pro­
gressive hearing loss due to cochlear degeneration was noticed in ad­
olescence in these subjects. Two male members (ages: 24 and 34 yr) 
of an unrelated Dutch family with a complete selective deficiency of 
MAO-A were also included in this study. Affected males in this fam­
ily have a point mutation of the MAO-A gene and are characterized 
clinically by borderline mental retardation and impaired impulse con­
trol (11, 12), In addition, the study included five male subjects (age: 
12-23 yr) from three different families, with a microdcletion of the X 
chromosomc, including the Norrie disease gene and the M AO-A and 
MAO-B genes (5-9). These latter subjects are characterized clinically 
by blindness and profound mental retardation.
29 males aged 21-55 yr (m ean±SD : 35±9 yr) served as a refer­
ence group for measurements of plasma catecholamincs and metabo­
lites. Subjects were not taking any medications and were all in good 
health as determined by a negative medical h is tory and a normal 
physical examination. These subjects were enlisted for study at two 
different institutions, The Clinical Center, National Institutes of 
Health (NIH), and the St. Radboud University Hospital. All proce­
dures were approved by the appropriate review committees, and in­
formed consent was obtained for all studies.
Procedures. Baseline venous blood samples were drawn after 15 
min of rest, and plasma and piatelet-rich plasma were separated by 
centrifugation at 4°C. Samples of plasma and platelet-rich plasma 
were stored at -80°C  until assayed for concentrations of catechol­
amines, metabolites, and 5-HT (8), and activities of platelet MAO-B 
and plasma amine oxidase. 24-h urine samples were collected and 
acidified to pH 2-3, and 20-ml aliquots were stored at -25°C  until as­
sayed. The two subjects with selective M AO-A deficiency received a 
simultaneous infusion of 3H-labeled NE and epinephrine (EPI) 
(l-2,5,6-[3H]NE, 40-60 Ci/mmol; L-N-methyl-[3H ]E PIf 65-75 Ci/ 
mmol [DuPont-New England Nuclear, ’s Hertogenbosch, The N eth­
erlands]) to calculate forearm spillovers of NE and normetanephrine 
(18). In these two subjects, a standardized tyramine infusion was also 
carried out to determine tyramine pressor sensitivity (19). To com­
pare neurochemical abnormalities in MAO-deficient subjects with 
changes occurring after pharmacological inhibition of MAO, 11 male 
subjects (m ean±SD  ages: 37±9 yr) with attention deficit hyperactiv­
ity disorder were studied before and after administration of deprenyl 
at a dose (60 mg daily for 6 wk) sufficient to inhibit both M AO-A and 
MAO-B (19),
DNA/genetic analysis. Genomic D N A  in the two MAO-B-defi- 
cient subjects was isolated from peripheral blood as described previ­
ously (20). DNA was digested by the restriction enzyme EcoRI, 
transferred to nylon membranes by Southern blotting, and hybridized 
to either 32P~labeled cosmid C5 (17) or to an MAO-B cDNA probe 
containing exons 3-15 (21). Hybridizing bands were visualized by 
overnight exposure of the membrane to film (X-omat S; Eastman 
Kodak Co., Rochester, NY). Hybridizing fragments were assigned to 
specific MAO-B exons based on published data (22). The detailed de­
scription of the genetic defects in the M A O -A - and M AO-AB-defi- 
cient subjects have been reported previously (5-8,10-12).
Enzyme activities and platelet 5-HT. Platelet-rich plasma was pre­
pared by differential centrifugation using ED TA  or acid citrate dex­
trose as anticoagulants. Platelet MAO-B and plasma amine oxidase 
activities were measured at the NIH, using 200 fiM methylene- 
[,4C]benzylamine (50 Ci/mmol; ICN Biomedicals Inc., Irvine, CA) as 
substrate (23). Measurements of platelet MAO activity were also car­
ried out at the Academic Medical Center (Amsterdam, The Nether­
lands) using a fluorimetric method with kynuramine as substrate (24).
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Platelet concentrations of 5-HT were measured at the NIH as de­
scribed previously (5).
Plasma neurochemical assays. All assays of plasma catecholamines 
and their metabolites were carried out at the NIH. The catechol­
amines NE, EPI, and dopamine (DA); the deaminated catecholamine 
metabolites 3,4-dihydroxyphenylglycoI (DHPG) and dihydroxyphe- 
nylacetic acid (DOPAC); and the catecholamine precursor dihydroxy- 
phenylalanine (DOPA) were extracted from 1-ml samples of plasma 
using alumina and quantified by liquid chromatography with electro­
chemical detection (25). The metanephrines—normetanephrine and 
metanephrine, O-methylated amine metabolites of N E and EPI, re­
spectively—were extracted from 2-ml samples of plasma using solid- 
phase ion exchange columns and quantified by liquid chromatogra­
phy with electrochemical detection (26). Timed collections of the 
catecholamine and metanephrine eluants leaving the electrochemical 
cell, followed by liquid scintillation spectroscopy, were used to deter­
mine plasma concentrations of 3H-labeled catecholamines and meta­
nephrines. Concentrations of sulfate-conjugated metanephrines were 
determined after deconjugation by incubation with sulfatase (Sigma 
Chemical Co., St. Louis, MO). Liquid chromatography with electro­
chemical detection was also used for measurement of the deaminated 
NE metabolite, 3-methoxy-4~hydroxyphenylglycol (MHPG), after 
extraction from plasma into ethylacetate (27). Concentrations of the 
DA metabolite, homovanillic acid (HVA), and of the final deami­
nated end-product of NE and EPI metabolism, vanillylmandelic acid 
(VMA), were measured by gas chromatography-mass spectrometry 
after ethylacetate extraction and derivatization with pentafluoropro- 
pionic anhydride (28).
Urine neurochemical assays. Urine concentrations of catechol­
amines and their metabolites were determined at two centers: the 
NIH and the Academic Medical Center. These measurements were 
carried out using gas chromatography-mass spectroscopy at the NIH 
(8, 28) and liquid chromatography with fluorimetric detection at the 
Academic Medical Center (29, 30). Urine concentrations of 5-HT 
were also measured at the latter center using liquid chromatography 
with fluorometric detection. Urine concentrations of trace amines 
(phenylethylamine, /?Myramine, and p-tyramine) were assayed at St. 
Elizabeth’s Hospital (Washington, DC) by gas chromatography-mass 
spectroscopy as described previously (31). Urine concentrations of 
catecholamines and their metabolites are reported as total concentra­
tions (free and conjugated). Some of the urine data for the MAO- 
A B - and MAO-A-deficient subjects have been reported elsewhere 
(5,6,8,11).
Data analysis. T he mean and SD of the plasma concentrations of 
catecholamines and metabolites in the 29 control subjects were calcu­
lated and served as the reference group for the tabulated data. Refer­
ence values for urine catecholamines and their metabolites were used 
from the original published methods. Differences between MAO- 
deficient subjects and control groups were tested by the Mann-Whit­
ney U lest. Within subject differences were determined using the Wil- 
coxon signed rank sum test. Differences were considered significant 
at P <  0,05 (two tailed). Ail values in the text are presented as 
mean±SEM , unless indicated otherwise.
Results
%
Clinical characteristics of the MA OS-deficient subjects. A gen­
eral physical examination of the two brothers with the MAO-B 
deficiency, including global neurological examination, was un­
remarkable. They have normal blood pressure and heart rate. 
They are blind and have impaired hearing as part of Norrie 
disease. Psychomotor development is normal. Both subjects 
have completed university degrees.
Delineation o f the X  chromosome microdeletion. We have 
previously reported that the deletion in these two brothers 
with Norrie disease extends from within the Norrie disease 
gene on the proximal side to within the MAO-B gene (17). 
Precise mapping of the deletion breakpoint was achieved by 
hybridization of the patients DNA to 13 cosmids derived from 
a 300-kb contig that encompasses the MAO-B and Norrie dis­
ease genes. In this way, the size of the deletion was estimated 
to be 150 kbp. Moreover, when cosmid C5 was used as a hy­
bridization probe on EcoRI-digested genomic DNA, four of 
the nine fragments were absent in the patient, and a putative 
deletion junction fragment of 2.5 kbp appeared (Fig. 2, left). 
Cosmid C5 had been shown previously to cover most of the 
MAO-B gene (17).
Deletion of the 5' end of the MAO-B gene was confirmed 
by hybridizing the same Southern blot to a cDNA probe con­
taining exons 3-15 of the MAO-B gene. This experiment dem­
onstrated deletion of exons 3-5 and an altered size of the frag­
ment containing exon 6 (Fig. 2, right). Based on these results, 
the distal deletion breakpoint is located in intron 5, between
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Figure 3. Overview of the MAO-A and MAO-B gene area in Xpl 1.3, 
based on Berger et al. (17) and Grimsby et al. (22). The location of 
the Norrie disease gene (ND ) is indicated. The molecular defect in 
three groups of patients is compared. MAOA, selective deficiency of 
MAO-A through a point mutation C to T in exon 8 of the MAO-A 
gene (Ref. 12, patients 3 and 4); MAOB , selective deficiency of 
MAO-B through a microdeletion encompassing the NDP gene and 
pari of the MAO-B gene, leaving MAO-A intact (patients 1 and 2 in 
this study); M AOA  -f MAOB , combined deficiency of M AO-A and 
MAO-B through a larger deletion encompassing all three genes, as 
well as the anonymous DNA marker LI.28 (DXS7).
exons 5 and 6 or possibly just within exon 6 (Fig. 3). Thus, the 
promoter, the transcription start site, and the first five exons 
that contain the DNA sequence encoding the first 159 amino 
acids of MAO-B are lacking in these patients.
Documentation of MAO-B deficiency. Both assays of plate­
let MAO-B activity, carried out at separate centers using either 
benzylamine or kynuramine as substrates, indicated undetect­
able levels of MAO-B activity in the two subjects with deletion 
of the MAO-B gene (Table I). Platelet MAO-B activity was 
also undetectable in patients with combined MAO-AB defi­
ciency, whereas it was normal in the subjects with selective
MAO-A deficiency. The activity of plasma amine oxidase was 
normal in all three subject groups (Table I).
Platelet 5-HT. The 5-HT content of platelets was within 
normal limits in the two subjects with MAO-B deficiency, 
whereas it was increased considerably in the groups with selec­
tive MAO-A and combined MAO-AB deficiencies (Table I).
Plasma concentrations o f catecholamines and metabolites. 
Plasma concentrations of NE and EPI were within the normal 
range in all MAO-deficient subjects (Table II). Plasma con­
centrations of DA were also normal in the subjects with selec­
tive deficiencies of MAO-B or MAO-A, whereas they were 
higher in patients with the combined MAO-AB deficiency 
than in control subjects (0.19±0.06 vs 0.07±0.01 pmol/ml; P < 
0.05). Plasma concentrations of free and sulfate-conjugated 
normetanephrine and metanephrine, the O-methylated amine 
metabolites of NE and EPI, were normal in MAO-B-deficient 
subjects, whereas both groups of MAO-A- and MAO-AB- 
deficient subjects showed considerable elevations above nor­
mal in plasma concentrations of free and sulfate-conjugated 
normetanephrine and sulfate-conjugated metanephrine (Table 
II). In contrast, all MAO-deficient subjects, apart from one 
MAO-AB-deficient patient (number 6), showed normal or 
only slightly elevated plasma concentrations of free metaneph­
rine. Thus, plasma concentrations of sulfate-conjugated meta­
nephrine in MAO-A- and MAO-AB-deficient subjects were 
elevated above mean concentrations of normal subjects more 
than concentrations of free metanephrine (4.5±0.53 vs 2.1 ± 
0.7-fold increase; P <  0.03). Similarly, plasma concentrations 
of sulfate-conjugated normetanephrine showed larger eleva­
tions in MAO-A- and MAO-AB-deficient subjects than con­
centrations of free normetanephrine (13.2±3,0 vs 6.5±0.6-fold 
increase; P <  0.02). Increases in plasma concentrations of free 
and sulfate-conjugated normetanephrine were larger (P < 
0.02) than those of metanephrine.
Plasma concentrations of DHPG, the deaminated metabo­
lite of NE and EPI, were normal in MAO-B-deficient sub­
jects, whereas they were reduced by >  95% in MAO-A sub­
jects and undetectable in four of the .five subjects with 
combined MAO-AB deficiency (Table II). A similar pattern
Table I. Platelet MAO Activity (in nmol/10Platelets per h)f with Benzylamine and with Kynuramine as Substrates, Platelet 5-HT 
(nmol/10 8 Platelets) and Plasma Amine Oxidase (nmol/ml per h)
Subject No.
MAO
deficiency
MAO-B activity 
platelets 
(benzylamine)
MAO-B activity 
platelets 
(kynuramine)
5-HT
platelets
Amîne oxidase 
plasma
1 B < 0 . 0 2 <  1.0 0.30 14.7
2 B <  0.02 < 1 . 0 0.17 16.4
3 A 11.21 25.5 1.73 22.4
4 A 12.10 22.5 1.59 15.4
5 AB < 0 . 0 2 ne ne 25.9
6 AB < 0 . 0 2 ne ne 33.1
7 AB <  0,02 ne ne 38.3
8 AB < 0 . 0 2 ne 2 .06 32.1
9 AB < 0 . 0 2 ne 2.51 15.7
Control subjects Mean 10.7 17.6 0.25 21.3
SD i.6 5.0 0.03 2.8
n 12 17 12 12
Compounds with abnormal values are depicted in bold. nes not examined.
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Table II. Plasma Concentrations (nmol/liter) o f Catecholamines and Metabolites in MAO-deficient Subjects and in Control 
Subjects
Catecholamines O-methylated amine metabolites Deaminated metabolites
Subject Deficiency NE EPI DA NMN NMN-SO*, MN MN-SO4 DHPG MHPG VMA DOPAC HVA
1 B 2.37 0.10 0.14 0.32 11.7 0.16 5.1 4.91 11.5 29.7 9.8 49.8
2 B 3.14 0.35 0.08 0.53 14.5 0.26 5.9 5.17 15.7 41.2 5.2 56.0
3 A 0.89 0.10 0.02 1.19 39.9 0.09 10.6 0.51 1,1 3.5 4.0 20.9
4 A 2.09 0.04 0.03 2.27 73.3 0.27 19.1 0.38 2.1 7.7 3.7 24.3
5 AB 4.10 0.32 0.03 1.78 106.0 0.25 14.1 < 0 .03 0.2 2.2 11.4 46.9
6 AB 2.66 0.17 0.15 1.97 86.1 0.95 16.4 < 0 .03 0.4 0.7 3.0 17.5
7 AB 2.16 0.10 0.27 1.46 92.6 0.20 15.8 < 0 .03 0.2 1.1 1.4 4.9
8 AB 2.91 0.11 0.37 2.29 234.0 0.23 9.4 0.12 0.3 2.2 0.5 12.1
9 AB 1.94 0.04 0.13 1.37 85.6 0.21 7.7 < 0 .03 0.1 0.6 0.3 2.3
Control Mean 1.35 0.14 0.08 0.25 7.5 0.16 3.1 5.54 14.3 31.1 9.1 51.9
subjects SD 0.59 0.09 0.04 0,11 5.0 0.06 1.2 1.37 2.1 2.5 5.6 9.0
n 29 27 11 29 27 27 26 29 17 10 21 11
Compounds with abnormal levels are depicted in bold. N M N , normetanephrine; NMN-SOj, sulfate-conjugated normetanephrine; MN, metaneph- 
rine; MN-S04, sulfate-conjugated metanephrine.
was observed for MHPG and VMA, the deaminated and 
O-methylated metabolites of NE and EPI; these metabolites 
were normal in MAO-B-deficient subjects, whereas they were 
reduced by 75-92% in the two MAO-A-deficient subjects and 
reduced further to > 93% in the subjects with the combined 
MAO-AB deficiency.
Since plasma concentrations of DHPG and sulfate-conju­
gated normetanephrine showed the largest reciprocal changes 
in MAO-AB-deficient subjects, the ratios of these metabolites 
were compared with those in normal subjects and patients re­
ceiving the MAO inhibitor, deprenyl (Fig. 4). Ratios of plasma 
concentrations of sulfate-conjugated normetanephrine to DHPG 
were within the normal range in the MAO-B-deficient sub­
jects, whereas these ratios were elevated by ^  100-fold in the
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Figure 4. The plasma normetanephrine (NMN)-S 0 4/D H P G  ra tio  in 
the patients with MAO deficiency, in control subjects, and in th e  sub 
jects treated with the MAO-B inhibitor, deprenyl. A B , c o m b in e d  
MAO-AB deficiency; A, MAO-A deficiency; B, MAO-B deficiency. 
The dashed lines represent the upper and lower reference v a lu e s  as 
determined from the 2.5 and 97.5 percentile values of the c o n t ro l  sub 
jects.
MAO-A-deficient subjects and by more than several thou­
sand-fold in all five subjects with the combined MAO-AB de­
ficiency. Similarly, in the subjects who received deprenyl, a 
250% increase in conjugated normetanephrine and a 60% de­
crease in plasma concentrations of DFIPG resulted in an in­
crease in the ratio of these two metabolites.
The deaminated metabolites of DA, DOPAC, and HVA 
showed a less marked and more variable trend than that ob­
served for the deaminated metabolites of NE and EPI (Table 
II). Again, plasma concentrations of these metabolites were 
normal in the two MAO-B-deficient subjects but reduced by 
53-60% in the MAO-A-deficient subjects. Plasma DOPAC 
and HVA tended to be reduced more in the combined MAO- 
AB-deficient subjects than in the two MAO-A-deficient sub­
jects, but there was considerable variability. In particular, one 
subject with combined MAO-AB deficiency showed normal 
concentrations of both DOPAC and HVA.
Plasma levels of DOPA, the catecholamine precursor, were 
normal in MAO-B-deficient subjects (7.65 and 7.54 nmol/li­
ter), but significantly lower in subjects with selective MAO-A 
and combined MAO-AB deficiencies than in control subjects 
(5.64±0.44 vs 8.55±0.40 nmol/liter, respectively; P < 0.01).
Urinary excretion o f catecholamines, catecholamine metab­
olites, 5-HT, and trace amines. The only abnormal neurochem­
ical finding in the MAO-B-deficient subjects was an increase 
in urinary phenylethylamine levels (Table III), Urinary excre­
tion of the other trace amines, meta- and paratyramine, was 
normal, as was that of the catecholamines, their O-methylated 
and deaminated metabolites, and 5-HT.
In contrast to the MAO-B-deficient subjects, the two sub­
jects with a selective deficiency of MAO-A showed increased 
excretion of 5-HT, normetanephrine, and the O-methylated 
amine metabolite of DA, 3-methoxytyramine (11). These sub­
jects also showed decreased or low-normal urinary excretion 
of the deaminated metabolites, MHPG, VMA, and HVA. Ex­
cretion of all trace amines was within normal limits.
In subjects with the combined MAO-AB deficiency, the 
urinary excretion of catecholamines and their metabolites
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Table IIL Urinary Excretion o f Catecholamines, Catecholamine Metabolites, 5-HT and Trace Amines in MAO-deficient Subjects 
and in Control Subjects (nmol/mmol Creatinine)
MAO
Subject No. deficiency
1
2
3
4
Controls of 
AMC
5
6
7
8
Controls of
NIH
B
B
Catecholamines O-methylated metabolites Deaminated metabolites Trace amines
NE EPI DA NMN MN 3-MT MHPG VMA HVA 5-HT PE m-Tyr p-Tyr
165
128
n e
26
558
536
203
131
72
44
76
126
900
700
1,300
1,900
1,700
1,500
50
57
76
207
35
48
271
320
A 62 8 730 392 56 217 100 200 400 124 4.0 18 499
A 142 11 803 666 82 318 200 400 500 233 8.0 33 201
AB 106 189 905 1,524 162 1,537 61 < 2 0 0 700 256 149 1,344 3,840
range 27-146 1.6-21 147-951 34-182 10-90 37-118 100-2,100 1,000-5,000 500-1,700 1.1-68 (Seie below)
AB 300 ne 2,666 2,537 166 1,766 86 251 2,005 ne 1,012 332 2,001
AB 461 ne 1,957 2,390 224 1,711 80 200 5,103 ne 1,816 425 2,492
AB 441 ne 1,920 2,908 247 2,910 111 508 2,266 ne 9,423 667 8,499
AB 388 ne 1,041 1,840 178 947 55 223 360 ne 4,159 1,030 5,295
Mean 180 516 240 63 40 805 1,849 3,564 6.8 43 361
SD 127 162 74 34 10 129 519 1,440 4.1 12 71
Compounds with abnormal values are depicted in bold. Academic Medical Center Amsterdam control values for catecholamines, catecholamine me­
tabolites, and 5-HT apply to subjects 1-4 and 9. National Institutes of Health control values for catecholamines and catecholamine metabolites apply 
to subjects 5-8. All trace amines were assayed at St. Elizabeth’s Hospital, Washington, DC. NMN, normetanephrine; M N , metanephrine; 3-MT , 
3-methoxytyramine; PE, phenylethylamine; m-Tyr, m-tyramine; p-Tyrt p-tyramine; A M C , Academic Medical Center Amsterdam; NIH, National In­
stitutes of Health; ne, not examined.
showed similar qualitative alterations as in subjects with the 
selective MAO-A deficiency but tended to be more variably 
disturbed (Table III). In particular, excretion of HVA showed 
highly variable changes compared with other subject groups. 
Similar to the situation in plasma, urinary levels of DA were 
also increased in patients with combined MAO-AB deficien­
cies but not in those with selective deficiencies of either iso­
enzyme.
Excretion of all trace amines was profoundly increased in 
patients with combined MAO-AB deficiency. In particular, 
excretion of phenylethylamine was increased substantially 
more in combined MAO-AB-deficient subjects than in selec­
tive MAOB-deficient subjects. Furthermore, whereas excre­
tion of the tyramine trace amines was normal in subjects with 
either selective deficiency of MAO-A or MAO-B, it was in­
creased considerably in subjects with the combined MAO-AB 
deficiency.
Forearm spillover o f NE and normetanephrine in MAO-A 
deficiency. Use of the tracer-labeled NE and EPI isotope dilu­
tion technique indicated an increase in forearm spillover into 
plasma of normetanephrine in the two MAO-A-deficient sub­
jects (Table IV). Forearm spillovers of normetanephrine from 
both circulating and locally released NE were increased. Fore­
arm spillover of NE was also increased in one of these subjects.
Tyramine sensitivity test. In one of the two MAO-A-defi­
cient subjects, systolic blood pressure was increased to the 30- 
mmHg end-point by an intravenous dose of tyramine of only
0.11 mg/min; this represents a dose less than one-tenth of that 
required in a control group of 11 patients with depression (19), 
and comparable to that in patients treated with selective 
MAO-A and nonselective MAO inhibitors (32), but about 
fourfold more than the end-point dose required in a juvenile
patient with combined MAO-AB deficiency (5). In the other 
MAO-A-deficient subject, the tyramine infusion had to be 
stopped prematurely at an infusion rate of 0.03 mg/min be­
cause of persisting oppressing pain in his chest. Systolic blood 
pressure had increased by 5 mmHg at this infusion rate.
Discussion
This is the first description of patients with a selective loss of 
MAO-B activity due to a disruption of the MAO-B gene on 
the X chromosome. This is also the first comprehensive report 
comparing neurochemical and clinical phenotypes in patients 
with selective deficiencies of MAO-A and MAO-B and com­
bined deficiencies of MAO-AB. The results demonstrate that 
the three groups of patients each display characteristic neuro-
Table IV. Forearm Spillover and Removal Rates o f NE  and 
Normetanephrine (NMN) in the Two Subjects with MAO-A 
Deficiency and in Control Subjects (n = 10)
Forearm NMN spillover
Subject NE spillover NE removal Circulating NE Local NE Total
3 262 185 6.7 153 160
4 643 406 25.7 268 294
Control subjects 388±199 245 ±155 3.6±5.6 51 ±52 54 ±52
Forearm normetanephrine spillovers represent those derived from fore­
arm removal of circulating NE, locally released NE, and the total of 
both. Values represent mean±SD (pmol/min). Abnormal values are de­
picted in bold.
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chemical profiles that may contribute to the different clinical 
phenotypes of each group.
Genotype and clinical phenotype of MAO-B deficiency pa­
tients. In addition to a partial deletion of the MAO-B gene, 
the gene for Norrie disease is also involved in the syndrome af­
fecting these two brothers. In fact, these patients were origi­
nally described as part of a previous study of Norrie disease 
that resulted in the cloning of the Norrie disease gene (17). Al­
though these subjects show the characteristic features of Nor­
rie disease, namely early onset blindness and progressive hear­
ing loss, they show no signs of physical or mental impairment. 
In particular, no signs of mental retardation or behavioral dis­
turbances have been noted as are observed in patients with 
classical Norrie disease combined with MAO-AB deficiency 
(5-8) or in subjects with selective MAO-A deficiency (11,12). 
Only a part of the MAO-B gene is deleted, but since this in­
cludes the DNA sequence encoding the first 159 amino acids 
of MAO-B, this is incompatible with any functional MAO-B 
activity. A complete and selective lack of MAO-B is docu­
mented by the undetectable levels of platelet MAO-B activity, 
determined by two different assay techniques, and is also 
reflected in the increased urinary phenylethylamine levels 
that are characteristically found with reduced MAO-B activ­
ity (33).
Metabolic roles o f MAO isoenzymes. Comparison of the se­
lective deficiencies of MAO-A and MAO-B and combined de­
ficiency of MAO-AB provides a unique insight into the meta­
bolic roles of the MAO isoenzymes in humans. This insight is 
not only important for interpreting the clinical consequences 
of MAO deficiency states, but also for understanding the basis 
of therapeutic interventions involving selective inhibition of 
MAO-A or MAO-B. Up until now, studies of the metabolic 
roles of MAO-A and MAO-B have been confined largely to 
pharmacological studies in animals or isolated tissues. Such 
studies are limited by a lack of completely selective MAO in­
hibitors as well as by difficulties in extrapolating the function 
of MAO from isolated tissues or animals to humans (3),
The severely impaired deamination of catecholamines in 
subjects with combined MAO-AB deficiency is demonstrated 
by the > 9 3 %  reductions in plasma concentrations of the 
deaminated catecholamine metabolites, DHPG, MHPG, and 
VMA. Additionally, the markedly elevated plasma concentra­
tions of O-methylated amine metabolites—free and sulfate- 
conjugated normetanephrine and sulfate-conjugated meta- 
nephrine—reflect impaired deamination of these metabolites 
as well as increased availability of the parent amines for 
O-methylation (14). Slightly less severe changes in patients 
with selective MAO-A deficiency and complete lack of similar 
directional changes in MAO-B-deficient subjects indicate that 
MAO-A is considerably more important than MAO-B for me­
tabolism of NE, EPI, and their O-methylated amine metabo­
lites in vivo. These findings agree with those in rats (14), where 
pharmacological inhibition of MAO-B failed to affect either 
the deaminated or O-methylated amine metabolites of NE and 
EPI, whereas inhibition of MAO-A resulted in similar direc­
tional changes to those observed here.
Larger increases in plasma concentrations and urinary ex­
cretion of normetanephrine than of metanephrine are also in 
agreement with results in rats or humans administered MAO 
inhibitors, a difference attributed to little deamination of EPI 
and metanephrine in the compartment where metanephrine is 
formed (14,15). The larger increases in plasma concentrations
of sulfate-conjugated than free metanephrines can be ex­
plained similarly by compartmentai differences in sites of for- 
mation. Over 90% of free metanephrine and a substantial, but 
lower, portion of free normetanephrine are formed within the 
adrenals (16, 18). In contrast, the conjugated metanephrines 
are not formed within the adrenals, but are formed elsewhere 
in the body where deamination is a more prominent pathway 
than in the adrenals.
As previously described (12), cultured skin fibroblasts of 
the two subjects with the selective MAO-A deficiency had no 
MAO-A activity. The present study extends the observation of 
MAO-A deficiency to the organ level and documents impaired 
extraneuronal deamination of NE and normetanephrine as in­
dicated by the increased forearm spillover of normetanephrine 
from locally released and circulating NE.
According to a study in isolated human brain tissue, DA 
was proposed as a selective substrate for MAO-B (34). How­
ever, studies of substrate specificity of the two forms of MAO 
in isolated tissues do not always reflect reliably the situation in 
vivo, and it has now been established that, under physiological 
conditions, DA is also a substrate for MAO-A (3). The de­
creases in plasma DOPAC and HVA, decreases in urinary ex­
cretion of HVA, and increases in urinary excretion of the
O-methylated DA metabolite, 3-methoxytyramine, in MAO- 
A-deficient subjects support an important role for MAO-A in 
the metabolism of DA. This finding and the complete lack of 
any similar directional changes in the MAO-B-deficient sub­
jects are in agreement with the results of individual blockade 
of the two isoenzymes in rats (14) and raise questions about 
whether MAO-B has any physiological role in the normal in 
vivo metabolism of DA.
The substantial decreases in deaminated catecholamine 
metabolites and increases in O-methylated amine metabolites 
in MAO-A-deficient but not MAO-B-deficient subjects indi­
cate that the two isoenzymes do not have equal complemen­
tary capacities for the deamination of catecholamines when 
one of the two isoenzymes is lacking. Nevertheless, the some­
what exaggerated neurochemical changes in patients with com­
bined MAO-AB deficiency compared with selective MAO-A 
deficiency indicate that MAO-B plays a minor auxiliary role in 
the metabolism of catecholamines when the activity of MAO-A 
is impaired. This conclusion is further supported by the ele­
vated plasma concentrations and urinary excretion of DA in 
MAO-AB-deficient subjects, but not in other groups. In rats, 
combined inhibition of the two MAO isoenzymes reduces the 
deamination of intravenously infused NE more than inhibition 
of MAO-A alone, whereas inhibition of MAO-B alone has no 
effect (14). The results indicate that, under normal conditions, 
MAO-B does not have a major role in the deamination of cat­
echolamines. Normal urinary and platelet levels of 5-HT in 
MAO-B-deficient subjects and substantial increases in selec­
tive MAO-A- and combined MAO-AB-deficient subjects 
also suggest that MAO-B is of less importance than MAO-A 
for the in vivo metabolism of 5-HT.
An important role for MAO-B is, however, evident for 
deamination of the trace amines, phenylethylamine and para- 
and metatyramine. Increased urinary phenylethylamine in 
MAO-B-deficient subjects represents the only neurochemical 
abnormality we could detect in these subjects. This increase 
contrasted with normal urinary phenylethylamine levels in 
MAO-A-deficient subjects, findings consistent with the reported 
preferential deamination of phenylethylamine by MAO-B (1,
1016 Lenders et al
33). The larger increases in phenylethylamine in the individu­
als with combined MAO-AB deficiencies relative to those 
with MAO-B deficiency alone indicate that MAO-A can par­
tially substitute for MAO-B in degrading this trace amine in 
vivo. In contrast to phenylethylamine, urinary tyramine excre­
tion was not increased in subjects with selective deficiency of 
MAO-B or MAO-A but was profoundly increased in MAO- 
AB-deficient subjects. This confirms that tyramine is a sub­
strate for both MAO-A and MAO-B (35) and represents one 
situation in which one isoenzyme is able to compensate fully 
for the absence of the other. Increased pressor sensitivity to 
tyramine in the subjects with selective deficiency of MAO-A 
observed here, in addition to that previously described in 
MAO-AB-deficient subjects described elsewhere (5), can be 
explained by dependence of these sensitivity changes on the 
capacity to deaminate both tyramine and the NE released 
from vesicles by tyramine (19). Predominance of MAO-A 
within sympathetic neurons (1), where tyramine exerts its 
pressor actions, is another factor.
Normal plasma concentrations of DOPA in MAO-B-defi- 
cient subjects and lowered concentrations in subjects with defi­
ciency of MAO-A, alone or in combination with MAO-B, reflect 
the important role of MAO-A in the metabolic degradation of 
NE within the neuronal cytoplasm (1). As previously demon­
strated, increased concentrations of NE in the neuronal 
cytoplasm during inhibition of intraneuronal MAO results in 
feedback inhibition of tyrosine hydroxylase and decreased for­
mation and plasma concentrations of the immediate product 
of the enzyme, DOPA (15,25,36).
The presence of detectable amounts of deaminated metab­
olites of catecholamines, particularly those of DA, in patients 
with neither MAO-A nor MAO-B activities indicates that 
these amines or their O-methylated derivatives are substrates, 
albeit weak substrates, for other enzymes that degrade amines. 
Plasma amine oxidase represents one such enzyme that in hu­
mans can deaminate both DA and its O-methylated metabo­
lite, 3-methoxytyramine (37, 38), and which is present at nor­
mal levels in patients with a lack of MAO isoenzymes.
MAO deficiency and behavior. MAO is a pivotal determi­
nant in the metabolism of amines that affect behavior and 
mood; pharmacological inhibition of MAO in animals and hu­
mans has profound effects on neurophysiological functioning 
(39, 40). Consequently, it has been assumed that genetically 
determined variations of MAO activity might be associated 
with behavioral and mood disorders. Numerous cross-sec­
tional studies have established an association between low 
platelet MAO-B activity and pathological behavior (41-43); a 
causal relation, however, has never been established. A lack of 
correlation in MAO-B activity between platelets and brain has 
been suggested (44). However, the amino acid sequences are 
identical (45), and the biochemical and pharmacological char­
acteristics of the isoenzyme in the two tissues are also similar 
(35), excluding a genetically encoded difference in the struc­
ture of the MAO-B isoenzyme between these tissues.
The present study shows that lack of MAO-B is associated 
with apparently normal behavior, whereas a lack of MAO-A is 
not (11, 12). In addition, the metabolic data in the MAO-B- 
deficient subjects indicate that an impairment in the break­
down of phenylethylamine is not related to abnormal behav­
ior. Normal phenylethylamine excretion in the selective 
MAO-A-deficient subjects further suggests that this trace 
amine is unlikely to be involved in the behavioral disorders
that characterize these patients.. These data do not, however, 
exclude a possible neuromodulatory function of phenylethyl­
amine in central nervous system catecholamine systems (46).
Despite the predominance of MAO-B over MAO-A in the 
human brain (3), the prominent disturbances in behavior in 
MAO-A-deficient subjects and the normal behavior in MAO- 
B-deficient subjects indicate that MAO-A plays a more vital 
role than MAO-B in the normal neurophysiological develop­
ment and function. This conclusion is consistent with the con­
siderably more important role of MAO-A compared with 
MAO-B in the metabolism of catecholamines and 5-HT re­
vealed by the present study. However, whether any of the 
profound neurochemical derangements observed in MAO-A- 
deficient subjects reflect the physiological basis of the behav­
ioral disorder in these subjects remains to be established.
A relationship between the observed neurochemical and 
behavioral abnormalities in MAO-A-deficient subjects is 
strongly supported by a recent study in transgenic mice with a 
deletion in the MAO-A gene (47). The severe behavioral dis­
turbances in these animals were associated with markedly ele­
vated brain 5-HT concentrations and could be reversed by 
postnatal administration of a 5-HT synthesis inhibitor. A 
causal relationship between altered 5-HT metabolism and dis­
turbed behavior was suggested to be mediated by discrete cor­
tical alterations induced by chronically elevated 5-HT levels. 
Further support for involvement of altered 5-HT metabolism 
is provided by another recent study, in which behavioral dis­
turbances in rats administered MAO inhibitors, before and af­
ter birth, were also associated with structural changes in brain 
serotoninergic systems (48). We have previously argued that 
the possible disruptive effect of raised 5-HT levels on the de­
veloping brain may help explain why impulsive aggressive be­
havior has been consistently associated with low levels of 5-HT 
or its primary metabolite, 5-hydroxyindol acetic acid, whereas 
5-HT levels are elevated in subjects with selective MAO-A de­
ficiency who show similar behavior (49).
The patients with combined deletions of the MAO-A and 
MAO-B genes also have deletions of the Norrie disease gene. 
However, the severe neurological symptoms and mental retar­
dation in these patients are not universal characteristics of pa­
tients with Norrie disease (8, 16). This is illustrated by the 
present patients with deletions of the MAO-B and Norrie dis­
ease genes, both of whom had completed university degrees 
and in whom the only symptoms were the early onset blind­
ness and impaired hearing. Despite the essentially normal neu­
rochemical profile in MAO-B-deficient patients, those with 
combined MAO-AB deficiency had somewhat more severe 
neurochemical changes than MAO-A-deficient patients, sug­
gesting that MAO-B may compensate, albeit to a limited ex­
tent, for lack of MAO-A. Thus, it is possible that the much 
more severe mental retardation and other neurological abnor­
malities observed in patients with combined MAO-AB (com­
pared with selective MAO-A deficiency) are due to additional 
deletion of the MAO-B gene. However, since the patients with 
combined MAO-AB deficiency have deletions of various sizes 
that possibly involve other genes on the X chromosome, other 
explanations should also be considered.
Neurochemical phenotyping may provide a sensitive tool 
for detection of the MAO-A deficiency state. In contrast to la­
borious methods of direct DNA analysis and measurements of 
fibroblast MAO-A activities, measurement of plasma cate­
cholamine metabolites provides a relatively simple screening
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procedure. In particular, use of the ratio of plasma concentra­
tions of sulfate-conjugated normetanephrine to plasma DHPG, 
which are the metabolites that show the most dramatic changes, 
provides a sensitive method for the detection of subjects sus­
pected of having reduced activity of MAO-A.
In conclusion, selective deficiency of MAO-B does not lead 
to a specific clinical phenotype and, in particular, is not associ­
ated with clinically apparent disturbances in behavior such as 
are observed in deficiencies of MAO-A, The absence in 
MAO-B-deficient patients of the severe neurochemical alter­
ations observed in patients with deficiencies of MAO-A or 
MAO-AB indicates that MAO-A is considerably more impor­
tant than MAO-B for metabolism of most biogenic amines. 
These functional differences in the two isoenzymes of MAO 
are likely to contribute to the different clinical phenotypes ob­
served in patients with deficiencies of either or both isoen­
zymes and may help in understanding the basis for therapeutic 
interventions involving specific inhibition of one or the other 
isoenzymes.
Acknowledgments
We gratefully acknowledge the contributions of our many co-authors 
on previously published papers who helped characterize the genetic, 
neurochemical, and behavioral features of the subjects reviewed in 
this paper. We also gratefully acknowledge the technical assistance of 
Jacques J. Willemsen, Douglas Hooper, Teresa Tolliver, and Jerry 
Oliver and the help of Marie-Cecile Jacobs in the studies of cate­
cholamine kinetics.
References
1. Youdim, J.P.M. Finberg, and K.F. Tipton. 1988. Monoamine ox­
idase. In Catecholamines 1. Handbook, of Experimental Pharmacology. U. 
Trendelenburg and N. Weiner, editors. Springer Verlag, New York. 119-192.
2. Weyler, W., Y.-P.P. Hsu, and X.O. Breakefield, 1990, Biochemistry and 
genetics of monoamine-oxidase. Pharmacol & Ther. 47:391-417.
3. Berry, M.D., A.V. Juorio, and I.A. Paterson. 1994. The functional role of 
monoamine oxidases A  and B in the mammalian central nervous system. Progr. 
NeurobioL (Oxf.). 42:375-391.
4. Kochersperger, L.M., E.L. Parker, M. Siciliano, G J . Darlington, and 
R.M. Denney. 1986. Assignment of genes for human monoamine oxidases A 
and B to the X-chromosome. J. Neurosci. 16:601-616.
5. Collins, F.A., D.L. Murphy, A.L. Reiss, K.B. Sims, J.G. Lewis, L. Freund,
F. Karoum, D. Zhu, I.H. Maumenee, and S.E. Antonarakis. 1992. Clinical, bio­
chemical and neuropsychiatric evaluation of a patient with a contiguous gene 
syndrome due to a microdeletion X pll.3  including the Norrie disease locus and 
monoamine oxidase (MAOA and MAOB) genes. Am. /  Med. Genet, 42:127- 
134.
6. Sims, K.B., A. de la Chapelle, R. Norio, E.-M. Sankila, Y.-P.P. Hsu, W.B. 
Rinehart, T.J. Corey, L. Ozelius, J.F, Powell, G. Bruns, et al. 1989. Monoamine 
oxidase deficiency in males with an X chromosome deletion. Neuron. 2:1069- 
1076.
7. Bleeker-Wagemakers, E.M., I. Zweije-Hofman, and A. Gal. 1988. Norrie 
disease as part of a complex syndrome explained by a submicroscopic deletion 
of the X chromosome. Ophthalmic. Paediatr. Genet. 9:137-142.
8. Murphy, D.L., K.B. Sims, F. Karoum, A. de la Chapelle, R. Norio, E.-M. 
Sankila, and X.O. Breakefield. 1990, Marked amine and amine metabolite 
changes in Norrie disease patients with an X-chromosomal deletion affecting 
monoamine oxidase./. Neurochem . 54:242-247.
9. Donnai, D., R.C. Mountford, and A.P. Read. 1988. Norrie disease result­
ing from a gene deletion: clinical features and DNA studies. J. Med. Genet. 25: 
73-78.
10. Murphy, D.L., K.B. Sims, F. Karoum, N.A. Garrick, A. de la Chapelle,
E.M. Sankila, R. Norio, and X.O. Breakefield. 1991. Plasma amine oxidase ac­
tivities in Norrie disease patients with an X-chromosomal deletion affecting 
monoamine oxidase./. Neural Transm. 83:1-12.
11. Brunner, H.G., M.R. Nelen, P. van Zandvoort, N.G.G.M, Abeling, 
A.H. van Gennip, E.C. Wolters, M.A. Kuiper, H.H. Ropers, and B.A. van 
Oost. 1993, X-linked borderline mental retardation with prominent behavioral 
disturbance: phenotype, genetic localization, and evidence for disturbed 
monoamine metabolism. Am. / .  Hum. Genet. 52:1032-1039.
12. Brunner, H.G., M. Nelen, X.O. Breakefield, H.H. Ropers, and B.A. van 
Oost. 1993. Abnormal behavior associated with a point mutation in the struc­
tural gene for monoamine oxidase A. Science (Wash. DC). 262:578-580.
13. Kopin, I.J. 1985. Catecholamine metabolism: basic aspects and clinical 
significance. Pharmacol Rev. 37:333-364.
14. Eisenhofer, G., and J.P.M. Finberg. 1994. Different metabolism of nore­
pinephrine and epinephrine by catechol-O-methyltransferase and monoamine 
oxidase in rats. /  Pharmacol. Exp . Ther. 268:1242-1251.
15. Eisenhofer, G., J.W.M. Lenders, J. Harvey-White, M. Ernst, A. Zamet- 
kin, D.L. Murphy, and I.J. Kopin. 1996. Differential inhibition of neuronal and 
extraneuronal monoamine oxidase. Neuropsychopharmacology. In press.
16. Eisenhofer, G., P. Friberg, K. Pacak, D.S. Goldstein; D.L. Murphy, 
C. Tsigos, A.A. Quyyumi, H.G. Brunner, and J.W.M. Lenders. 1995. Plasma 
metadrenalines: do they provide useful information about sympatho-adrenal 
function and catecholamine metabolism? Clin. Sci. (Land.), 88:533-542.
17. Berger, W., A. Meindl, T.J.R. van de Pol, F.P.M. Cremers, H.H. Ropers,
C. Doerner, A. Monaco, A.A.B. Bergen, R. Lebo, M. Warburg, et al. 1992. Iso­
lation of a candidate gene for Norrie disease by positional cloning. Nat. Genet. 
1:199-203.
18. Eisenhofer, G., B. Rundquist, A. Àneman, P. Friberg, N. Dakak, I.J. 
Kopin, M.C. Jacobs, and J.W.M. Lenders. 1995. Regional release and removal 
of catecholamines and extraneuronal metabolism to metanephrines. Clin. 
Endocrinol & Metab. 80:3009-3017.
19. Sunderland, T., E.A. Mueller, R,M. Cohen, D.C. Jimerson, D. Pickar, 
and D.L. Murphy. 1985. Tyramine pressor sensitivity changes during deprenyl 
treatment. Psychopharmacology. 86:432-437.
20. Miller, S.A., D.D. Dykes, and H.F. Polesky. 1988. A simple salting out 
procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 
16:1215.
21. Sims, K,B,, R.V. Lebo, G, Benso, C. Shalish, D. Schuback, Z.Y. Chen,
G. Bruns, I.W. Craig, M.S. Golbus, and X.O. Breakefield. 1992. The Norrie dis­
ease gene maps to a 150 kb region on chromosome X pll,3 . Hum. Mol. Genet. 
1:83-89.
22. Grimsby, J., K. Chen, L.-J. Wang, N.C. Lan, and J.C. Shih, 1991. Human 
monoamine oxidase A and B genes exhibit identical exon-intron organization. 
Proc. Natl Acad. Sci USA. 88:3637-3641.
23. Murphy, D.L., C. Wright, M. Buchsbaum, J. Costa, A. Nichols, and 
R. Wyatt. 1976. Platelet and plasma amine activities in 650 normals: sex and age 
differences and stability over lime. Biochem, Med, 16:254-265.
24. van Kempen, G.M.J., J.L. van Brussel, and E J.M . Penning, 1985. Assay 
of platelet monoamine oxidase in whole blood. Clin. Chim. Acta. 153:197-202,
25. Eisenhofer, G., D.S. Goldstein, R. Stull, H.R. Keiser, T, Sunderland,
D,L. Murphy, and I.J. Kopin. 1986. Simultaneous liquid chromatographic de­
termination of 3,4-dihydroxyphenyiglycol, catecholamines, and 3,4-dihydroxy- 
phenylalanine in plasma and their responses to inhibition of monoamine oxi­
dase. Clin. Chem. 32:2030-2033.
26. Lenders, J.W.M., G. Eisenhofer, I. Armando, H.R. Keiser, D.S. Gold­
stein, and I J .  Kopin, 1993. Determination of metanephrines in plasma by liquid 
chromatography with electrochemical detection. Clin. Chem. 39:97-103.
27. Eisenhofer, G., W, Pecorella, K. Pacak, D. Hooper, I.J. Kopin, and D.S. 
Goldstein. 1994. The neuronal and cxtra-neuronal origins of plasma 3-methoxy- 
4-hydroxyphenylglycol in rats./. Auton. Nerv. Syst. 50:93-107.
28. Karoum, F. 1983. Mass fragmentography in the analysis of biogenic 
amines: a clinical, physiological, and pharmacological evaluation. In Methods in 
biogenic amine research. S. Parvez, T. Nagatsu, I. Nagatsu, and H. Parvez, edi­
tors. Elsevier, New York. 237-255.
29. Stroomer, A.E.M., H. Overmars, N.G.G.M. Abeling, and A.H. Van 
Gennip. 1990, Simultaneous detection of acidic 3,4-dihydroxyphenylaIanine 
metabolites and 5-hydroxy-indole-3-acetic acid in urine by high-performance 
liquid chromatography. Clin, Chim. Acta. 36:1834-1837.
30. Abeling, N.G., A.H. van Gennip, H. Ovcrmars, and P.A. Votile, 1984. 
Simultaneous determination of catecholamines and metanephrines in urine by 
HPLC with fluorimetrie detection. Clin. Chim. Acta. 137:211-226,
31. Karoum, F.f H. Nasrallah, S. Potkin, L. Chuang, J. Moyer-Schwing, I. Phil­
lips, and R.J. Wyatt. 1979. Mass fragmentography of phenylethylamine, m~ and 
p-ty ramine, and related amines in plasma, cerebrospinal fluid, urine and brain. 
/ .  Neurochem. 33:201-202.
32. Pickar, D., R.M. Cohen, D.C. Jimerson, and D.L. Murphy. 1981. 
Tyramine infusions and selective monamine oxidase inhibitor treatment. I, 
Changes in pressor sensitivity. Psychopharmacology. 74:4-7.
33. Murphy, D.L., F. Karoum, I. Alterman, S. Lipper, and R.J, Wyatt. 1984, 
Phenylethylamine, tyramine and other trace amines in patients with affective 
disorders: associations with clinical state and antidepressant drug treatment, hi 
Neurobiology of the trace amines. A.A. Boulton, G.B. Baker, W.G. Dewhurst, 
and M. Sandler, editors. Humana Press, Clifton, NJ. 449-514.
34. Glover, V., M. Sandler, F. Owen, and G.J. Riley. 1977. Dopamine is a 
monoamine oxidase B substraLe in man. Nature (Land.). 265:80-81.
35. Donnelly, C.H., and D.L. Murphy. 1977. Substrate- and inhibitor- 
related characteristics of human platelet monoamine oxidase. Biochem. Phar­
macol 26:853-858.
36. Eisenhofer, G., D.S. Goldstein, T.G. Ropchak, and I.J. Kopin. 1988. 
Source and physiological significance of plasma 3,4-dihydroxyphenylalamine in 
the rat. J. Neurochem. 51:1204-1213.
1018 Lenders et al
37. Buffoni, F. 1966. Histaminasc and related amine oxidases. Pharmacol 
Rev. 18:1163-1199.
38. McEwan, C.M. 1965. Human plasma monoamine oxidase. J. B iol 
Chem. 240:2003-2010.
39. Campbell, I.C., D.S. Robinson, W, Lovenberg, and D.L. Murphy. 1979. 
The effects of chronic regimens of clorgyline and pargyline on monoamine oxi­
dase metabolism in the rat brain. J. Neurochem. 32:49-55.
40. Murphy, D.L., N.A. Garrick, and R.M. Cohen. 1983. Monoamine oxi­
dase inhibitors and monoamine oxidase: biochemical and physiological aspects 
relevant to human psycho-pharmacology. In  Antidepressants. G.D. Burrows, 
T.R. Norman, and B. Davies, editors. Elsevier, Amsterdam. 209-227.
41. Buchsbaum, M.S., R.D. Coursey, and D.L. Murphy. 1976. The biochem­
ical high-risk paradigm: behavioral and familial correlates of low-platclct 
monamine oxidase activity. Science (Wash. DC). 194:339-341.
42. von Knorring, L., L. Oreland, and B. Winblad, 1984. Personality traits 
related to monoamine oxidase activity in platelets. Psychiatr. Res. 12:11-26.
43. Dcvor, E.J., C.R. Cloninger, P.L. Hoffman, and B. Tabakoff. 1993. As­
sociation of monoamine oxidase (MAO) activity with alcoholism and alcoholic 
subtypes. Am. J. Med. Genet. 48:209-213.
44. Young, W.F., E. Laws, F.N. Sharbrough, and R.M. Weinshilbaum. 1986. 
Hum an monoamine oxidase, lack of brain and platelet correlation. Arch, Gen. 
Psychiatry. 43:604-609.
45. Chen, K., H.-F. Wu, and J.C. Shih. 1993. The deduced amino acid se­
quences o f human platelet and frontal cortex monoamine oxidase B are identi­
ca l./ .  Neurochem. 61:187—190.
46. Paterson, I.A., A.V. Juorio, and A.A. Boulton. 1990. 2-Phenyletli- 
ylamine: a modulator of catecholamine transmission in the mammalian central 
nervous system? J, Neurochem. 55:1827-1837.
47. Cases, O., I. Seif, J. Grimsby, P. Gaspar, K. Chen, S. Pournin, U. Müller, 
M. Aguet, C. Babinet, J. C. Shih, and E. D c Maeyer. 1995. Aggressive behavior 
and altered amounts of brain serotonin and norepinephrine in mice lacking 
M A O -A . Science (Wash. DC). 268:1763-1766.
48. Whitaker-Azmitia, P.M., X. Zhang, and C. Clarke. 1994. Effects of ges­
tational exposure to monoamine oxidase inhibitors in rats: preliminary behav­
ioral and neurochemical studies. Neuropsychopharmacology. 11:125-132.
49. Brunner, H.G. 1995. M A O A  deficiency and abnormal behaviour per­
spectives on an association. In Genetics of Criminal and Antisocial Behaviour. 
M. Rutter, editor. Wily Liss, Chichester, U K . 155-167.
Genetic Deficiencies o f  Monoamine Oxidase-A and -B 1019
